FI964784A - Virusrekombinanter, framställning och användning i genterapi - Google Patents

Virusrekombinanter, framställning och användning i genterapi Download PDF

Info

Publication number
FI964784A
FI964784A FI964784A FI964784A FI964784A FI 964784 A FI964784 A FI 964784A FI 964784 A FI964784 A FI 964784A FI 964784 A FI964784 A FI 964784A FI 964784 A FI964784 A FI 964784A
Authority
FI
Finland
Prior art keywords
preparation
gene therapy
virus recombinants
recombinant viruses
therapy
Prior art date
Application number
FI964784A
Other languages
English (en)
Finnish (fi)
Other versions
FI120154B (sv
FI964784A0 (sv
Inventor
Patrick Benoit
Patrice Denefle
Michel Perticaudet
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9463811&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI964784(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of FI964784A publication Critical patent/FI964784A/sv
Publication of FI964784A0 publication Critical patent/FI964784A0/sv
Application granted granted Critical
Publication of FI120154B publication Critical patent/FI120154B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01034—Lipoprotein lipase (3.1.1.34)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FI964784A 1994-06-02 1996-11-29 Rekombinant-DNA-virus, farmaceutisk sammansättning innehållande desamma, däggdjurcell, som är infekterad med desamma och implantat, som omfattar celler FI120154B (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR9406759 1994-06-02
FR9406759A FR2720756B1 (fr) 1994-06-02 1994-06-02 Virus recombinants, préparation et utilisation en thérapie génique.
PCT/FR1995/000669 WO1995033840A1 (fr) 1994-06-02 1995-05-22 Virus recombinants, preparation et utilisation en therapie genique
FR9500669 1995-05-22

Publications (3)

Publication Number Publication Date
FI964784A true FI964784A (sv) 1996-11-29
FI964784A0 FI964784A0 (sv) 1996-11-29
FI120154B FI120154B (sv) 2009-07-15

Family

ID=9463811

Family Applications (1)

Application Number Title Priority Date Filing Date
FI964784A FI120154B (sv) 1994-06-02 1996-11-29 Rekombinant-DNA-virus, farmaceutisk sammansättning innehållande desamma, däggdjurcell, som är infekterad med desamma och implantat, som omfattar celler

Country Status (14)

Country Link
US (1) US20130210898A1 (sv)
EP (1) EP0763116B2 (sv)
JP (1) JPH10500859A (sv)
AT (1) ATE248920T1 (sv)
AU (1) AU2620595A (sv)
CA (1) CA2190394C (sv)
DE (1) DE69531678T3 (sv)
FI (1) FI120154B (sv)
FR (1) FR2720756B1 (sv)
IL (1) IL113978A (sv)
MX (1) MX9605988A (sv)
NO (1) NO964894L (sv)
WO (1) WO1995033840A1 (sv)
ZA (1) ZA954386B (sv)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6814962B1 (en) * 1994-06-02 2004-11-09 Aventis Pharma S.A. Recombinant viruses and their use for treatment of atherosclerosis and other forms of coronary artery disease and method, reagent, and kit for evaluating susceptibility to same
US5658729A (en) 1994-10-11 1997-08-19 The University Of British Columbia Method, reagent and kit for evaluating susceptibility to premature atherosclerosis
FR2720756B1 (fr) * 1994-06-02 1996-07-12 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0599859A1 (en) * 1991-06-25 1994-06-08 Novo Nordisk A/S Mammalian pancreatic lipase and variant thereof
FR2720756B1 (fr) * 1994-06-02 1996-07-12 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
FR2749857B1 (fr) * 1996-06-12 1998-08-14 Centre Nat Rech Scient Generation de molecules replicatives in vivo

Also Published As

Publication number Publication date
FI120154B (sv) 2009-07-15
EP0763116A1 (fr) 1997-03-19
NO964894D0 (no) 1996-11-18
CA2190394A1 (fr) 1995-12-14
DE69531678T2 (de) 2004-07-08
WO1995033840A1 (fr) 1995-12-14
EP0763116B1 (fr) 2003-09-03
NO964894L (no) 1996-11-18
IL113978A (en) 2006-06-11
CA2190394C (fr) 2008-10-14
FR2720756A1 (fr) 1995-12-08
JPH10500859A (ja) 1998-01-27
EP0763116B2 (fr) 2008-04-23
IL113978A0 (en) 1995-10-31
MX9605988A (es) 1997-12-31
ATE248920T1 (de) 2003-09-15
FI964784A0 (sv) 1996-11-29
DE69531678D1 (de) 2003-10-09
ZA954386B (en) 1996-03-15
AU2620595A (en) 1996-01-04
US20130210898A1 (en) 2013-08-15
DE69531678T3 (de) 2009-01-29
FR2720756B1 (fr) 1996-07-12

Similar Documents

Publication Publication Date Title
EP1005376A4 (en) METHODS AND COMPOSITIONS FOR USE IN GENE THERAPY IN THE TREATMENT OF HEMOPHILIA
HK1214298A1 (zh) 用於疫苗和基因治療的重組流感病毒
EP1312679B8 (en) Recombinant MVA virus, and the use thereof
EP1115290A4 (en) COMMUNICATION SYSTEM AND CORRESPONDING USE METHOD
ZA942778B (en) Recombinant viruses, and their preparation and use in gene therapy.
IL181695A0 (en) Methods for cultivating cells and propagating viruses
ZA958128B (en) Viral vectors and use in gene therapy
FI964784A (sv) Virusrekombinanter, framställning och användning i genterapi
DE69536025D1 (de) Methode zur direkten Klonierung von Nukleasegenen in E.coli
AU7514087A (en) Vaccine containing the protein f of the aids virus
FR2717495B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
DE69726602D1 (en) Hepatitis b inhibitoren
HUP0103871A2 (hu) Rekombináns CELO-vírus és CELO vírus DNS
IL112992A0 (en) Recombinant viruses, their preparation and their use in gene therapy
FR2717823B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
FR2717497B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
MX9706569A (es) Virus recombinantes que expresan la lecitina-colesterol aciltransferasa y sus usos en terapia genica.
MY157873A (en) Recombinant mva virus, and the use thereof
MY134484A (en) Recombinant mva virus, and the use thereof

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: AVENTIS PHARMA S.A.

FG Patent granted

Ref document number: 120154

Country of ref document: FI

SPCF Supplementary protection certificate application filed

Spc suppl protection certif: C20130023

SPCG Supplementary protection certificate granted

Spc suppl protection certif: 400

Extension date: 20200522

MA Patent expired